Compare AstraZeneca plc (AZN) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? AstraZeneca plc trades at $158.59 (market cap $248.14B), while iShares 10 20 Year Treasury Bond ETF trades at $96.63. The key difference: AstraZeneca plc pays a 2.01% dividend while iShares 10 20 Year Treasury Bond ETF pays none, and AstraZeneca plc is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| AZN | TLH | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Fixed Income |
52-Week High | $209.48 | $105.36 |
52-Week Low | $147.06 | $96.39 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
TLH trades at $96.86, up 0.49% today, but technical indicators signal a bearish trend with moving averages and ADX pointing downward. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent corporate actions include consistent dividend payments, with the latest being $0.38 per share scheduled for August 2026. Market sentiment is influenced by broader economic factors like rising Treasury yields and oil price volatility, as highlighted in recent financial news.
The outlook for TLH is cautious due to weak technical momentum and absent key financial metrics, though dividend stability offers some support. Risks include macroeconomic pressures from potential Fed rate hikes and inflation. Investors should seek updated earnings reports for fundamental reassessment, as current data gaps hinder a full evaluation of growth prospects or valuation attractiveness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
